Get the Stockscreener App
82.43
1.28%
1.04
Pre-market:
82.41
-0.02
-0.02%
Apogee Therapeutics Inc stock is traded at $82.43, with a volume of 369.90K.
It is up +1.28% in the last 24 hours and down -9.28% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$81.39
Open:
$80.41
24h Volume:
369.90K
Relative Volume:
0.43
Market Cap:
$6.21B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-19.05
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
-1.76%
1M Performance:
-9.28%
6M Performance:
+24.40%
1Y Performance:
+105.15%
1-Day Range:
$75.00
$83.24
1-Week Range:
$75.00
$84.44
52-Week Range:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
82.43 | 6.14B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics Insider Sold Shares Worth $1,641,711, According to a Recent SEC Filing - Moomoo
How (APGE) Movements Inform Risk Allocation Models - Stock Traders Daily
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales - simplywall.st
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics, Inc.Common Stock (NQ: APGE - FinancialContent
Jefferies raises Apogee Therapeutics stock price target on trial outlook By Investing.com - Investing.com Nigeria
Jefferies raises Apogee Therapeutics stock price target on trial outlook - Investing.com
APGE Stock Price, Quote & Chart | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Form 144 | Apogee Therapeutics(APGE.US) Officer Proposes to Sell 4.95 Million in Common Stocks - Moomoo
APGE (APGE) Form 144: Insider-related sale notices, 60,000 shares planned - Stock Titan
Apogee Therapeutics (APGE) Gets a Buy from Wedbush - The Globe and Mail
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $100 to $137 - Moomoo
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $130 - Moomoo
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - 富途牛牛
Apogee Therapeutics Q1 2026 10-Q: Financial Results, Key Risks, and Forward-Looking Statements - Minichart
Apogee Therapeutics (NASDAQ:APGE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Apogee Therapeutics Reports Strong Q1 2026 Results and Pipeline Progress for Zumilokibart in Atopic Dermatitis and Asthma 12 - Minichart
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Apogee Therapeutics Q1 Net Loss Widens - Moomoo
Apogee Therapeutics 1Q 2026: Net loss $(74.1M), No product revenue — 10-Q Summary - TradingView
Apogee Therapeutics (NASDAQ: APGE) reports cash runway and Phase 2 AD data - Stock Titan
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, vs. FactSet Est of $74.2M - marketscreener.com
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, Vs. FactSet Est of $74.2M - Moomoo
Apogee Therapeutics (Nasdaq: APGE) Q1 loss widens, cash runway to 2029 - Stock Titan
Apogee's AD drug zumilokibart keeps 52-week response with 3- and 6-month dosing - Stock Titan
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - Moomoo
Apogee Therapeutics Insider Sold Shares Worth $462,784, According to a Recent SEC Filing - marketscreener.com
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares - Investing.com India
Apogee Therapeutics (APGE) CMO sells 5,500 shares, exercises 4,125 options - Stock Titan
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN
Trading Systems Reacting to (APGE) Volatility - Stock Traders Daily
Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold - Stock Titan
Should Zumilokibart’s Phase 2 Data and Insider Sales Activity Require Action From Apogee Therapeutics (APGE) Investors? - Sahm
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Jane - Moomoo
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Apogee Therapeutics (APGE) - The Globe and Mail
Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan
Rothschild & Co Redburn Initiates Apogee Therapeutics at Buy - Moomoo
Apogee Therapeutics Price Target Announced at $140.00/Share by Rothschild & Co - Moomoo
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo
Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.72%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):